March 25th 2023
This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.
March 22nd 2023
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Is There a Preferred β-Lactam/β-Lactamase Inhibitor Agent for Treatment of KPC-Producing Enterobacterales Infection?February 22nd 2023
Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.
Restoring Hope by Restoring Gut Flora: Rebyota and the Future of Combating Recurrent CDIFebruary 18th 2023
Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.
Safety of Cefazolin Has Been Underestimated for GBS Prophylaxis During LaborFebruary 17th 2023
Both undertreatment and overtreatment were common in this cohort of penicillin-allergic pregnant women with Group B Streptococcus (GBS).
Linezolid Coadministration With Medications for Opioid Use Disorder: A Serotonin Toxicity Tightrope?February 16th 2023
This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.
Inappropriate Prescribing of Antibiotics Associated with Increased Costs, Adverse EventsFebruary 13th 2023
Six respiratory infections are among the most common diagnoses for which antibiotics often are inappropriately prescribed, and new research sheds light on the effects, both in increased risk of adverse events and excess health care costs.
Males Found to be More Susceptible to Respiratory Bacterial InfectionsJanuary 12th 2023
A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.
Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric InfectionsJanuary 4th 2023
In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022December 24th 2022
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Challenges in the Management of Mycobacterium abscessus Complex
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.